Autocrine VEGF/VEGFR1 signaling in a subpopulation of cells associates with aggressive osteosarcoma

Molecular Cancer Research

Volumn 12, Issue 8, 2014, Pages 1100-1111

  Ohba, Tetsuro ^a,c   Cates, Justin M M ^a   Cole, Heather A ^a   Slosky, David A ^a   Haro, Hirotaka ^c   Ando, Takashi ^c   Schwartz, Herbert S ^a   Schoenecker, Jonathan G ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER SURVIVAL; CELL PROLIFERATION; CELL SUBPOPULATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; BONE TUMOR; GENETICS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE;

ANIMALS; AUTOCRINE COMMUNICATION; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; OSTEOLYSIS; OSTEOSARCOMA; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84905986703     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0037     Document Type: Article

References (29)

1. Ward WG, Mikaelian K, Dorey F, Mirra JM, Sassoon A, Holmes EC, et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 1994;12:1849-58. (Pubitemid 24349387)
2. Wunder JS, Nielsen TO, Maki RG, O'Sullivan B, Alman BA. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 2007;8:513-24. (Pubitemid 46823060)
3. Noh K, Kim KO, Patel NR, Staples JR, Minematsu H, Nair K, et al. Targeting inflammatory kinase as an adjuvant treatment for osteosarcomas. J Bone Joint Surg Am 2011;93:723-32.
4. Yu XW, Wu TY, Yi X, Ren WP, Zhou ZB, Sun YQ, et al. Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis. Tumour Biol 2014;35:155-60.
5. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80. (Pubitemid 35266299)
6. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207-25. (Pubitemid 32176299)
7. Savitskaya YA, Rico-Martinez G, Linares-Gonzalez LM, Delgado-Cedillo EA, Tellez-Gastelum R, Alfaro-Rodriguez AB, et al. Serum tumor markers in pediatric osteosarcoma: a summary review. Clin Sarcoma Res 2012;2:9.
8. Rastogi S, Kumar R, Sankineani SR, Marimuthu K, Rijal L, Prakash S, et al. Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study. Intl Orthop 2012;36:2315-21.
9. Yin D, Jia T, Gong W, Yu H, Wooley PH, Mott MP, et al. VEGF blockade decelerates the growth of a murine experimental osteosarcoma. Int J Oncol 2008;33:253-9.
10. Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 2012;72:1909-14.
11. Abdullah SE, Perez-Soler R. Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer 2012;118:3455-67.
12. Mross K, Frost A, Steinbild S, Hedbom S, Buchert M, Fasol U, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012;18:2658-67.
13. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76. (Pubitemid 36749215)
14. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27. (Pubitemid 46202320)
15. Vincent L, Jin DK, Karajannis MA, Shido K, Hooper AT, Rashbaum WK, et al. Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells. Cancer Res 2005;65:3185-92. (Pubitemid 40524600)
16. Lee TH, Seng S, Sekine M, Hinton C, Fu Y, Avraham HK, et al. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med 2007;4:e186.
17. Luu HH, Kang Q, Park JK, Si W, Luo Q, Jiang W, et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 2005;22:319-29. (Pubitemid 41374288)
18. Schmidt J, Strauss GP, Schon A, Luz A, Murray AB, Melchiori A, et al. Establishment and characterization of osteogenic cell lines from a spontaneous murine osteosarcoma. Differentiation 1988;39:151-60. (Pubitemid 19082658)
19. Ning Y, Chen S, Li X, Ma Y, Zhao F, Yin L. Cholesterol, LDL, and 25-hydroxycholesterol regulate expression of the steroidogenic acute regulatory protein in microvascular endothelial cell line (bEnd.3). Biochem Biophys Res Commun 2006;342:1249-56.
20. Ichikawa J, Cole HA, Magnussen RA, Mignemi NA, Butler M, Holt GE, et al. Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: Procoagulant nature of osteosarcoma. Cancer 2012;118:2494-506.
21. Cole HA, Ichikawa J, Colvin DC, O'Rear L, Schoenecker JG. Quantifying intra-osseous growth of osteosarcoma in a murine model with radiographic analysis. J Orthop Res 2011;29:1957-62.
22. Nyangoga H, Mercier P, Libouban H, Basle MF, Chappard D. Three-dimensional characterization of the vascular bed in bone metastasis of the rat by microcomputed tomography (MicroCT). PLoS ONE 2011;6:e17336.
23. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis 2000;18:261-71. (Pubitemid 32269996)
24. Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 2001;61:3750-9. (Pubitemid 32694989)
25. Lee YH, Tokunaga T, Oshika Y, Suto R, Yanagisawa K, Tomisawa M, et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 1999;35:1089-93. (Pubitemid 29339192)
26. Hassan SE, Bekarev M, Kim MY, Lin J, Piperdi S, Gorlick R, et al. Cell surface receptor expression patterns in osteosarcoma. Cancer 2012;118:740-9.
27. Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P, Sibilia M. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 2010;140:268-79.
28. Frank NY, Schatton T, Kim S, Zhan Q, Wilson BJ, Ma J, et al. VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res 2011;71:1474-85.
29. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000;6:572-7. (Pubitemid 30111481)